Rachel C Nolan1, Omar Akhand, John-Ross Rizzo, Steven L Galetta, Laura J Balcer. 1. Departments of Neurology (RCN, OA, JRR, SLG, LJB), Population Health (LJB), Ophthalmology (SLG, LJB), and Physical Medicine and Rehabilitation (JRR), New York University School of Medicine, New York, New York.
Abstract
: BACKGROUND: : The visual pathways are increasingly recognized as an ideal model to study neurodegeneration in multiple sclerosis (MS). Low-contrast letter acuity (LCLA) and optical coherence tomography (OCT) are validated measures of function and structure in MS. In fact, LCLA was the topic of a recent review by the Multiple Sclerosis Outcome Assessments Consortium (MSOAC) to qualify this visual measure as a primary or secondary clinical trial endpoint with the Food and Drug Administration (FDA) and other regulatory agencies. This review focuses on the use of LCLA and OCT measures as outcomes in clinical trials to date of MS disease-modifying therapies. METHODS: A Pubmed search using the specific key words "optical coherence tomography," "low-contrast letter acuity," "multiple sclerosis," and "clinical trials" was performed. An additional search on the clinicaltrials.gov website with the same key words was used to find registered clinical trials of MS therapies that included these visual outcome measures. RESULTS: As demonstrated by multiple clinical trials, LCLA and OCT measures are sensitive to treatment effects in MS. LCLA has been used in many clinical trials to date, and findings suggest that 7 letters of LCLA at the 2.5% contrast level are meaningful change. Few clinical trials using the benefits of OCT have been performed, although results of observational studies have solidified the ability of OCT to assess change in retinal structure. Continued accrual of clinical trial and observational data is needed to validate the use of OCT in clinical trials, but preliminary work suggests that an intereye difference in retinal nerve fiber layer thickness of 5-6 μm is a clinically meaningful threshold that identifies an optic nerve lesion in MS. CONCLUSIONS: Visual impairment represents a significant component of overall disability in MS. LCLA and OCT enhance the detection of visual pathway injury and can be used as measures of axonal and neuronal integrity. Continued investigation is ongoing to further incorporate these vision-based assessments into clinical trials of MS therapies.
: BACKGROUND: : The visual pathways are increasingly recognized as an ideal model to study neurodegeneration in multiple sclerosis (MS). Low-contrast letter acuity (LCLA) and optical coherence tomography (OCT) are validated measures of function and structure in MS. In fact, LCLA was the topic of a recent review by the Multiple Sclerosis Outcome Assessments Consortium (MSOAC) to qualify this visual measure as a primary or secondary clinical trial endpoint with the Food and Drug Administration (FDA) and other regulatory agencies. This review focuses on the use of LCLA and OCT measures as outcomes in clinical trials to date of MS disease-modifying therapies. METHODS: A Pubmed search using the specific key words "optical coherence tomography," "low-contrast letter acuity," "multiple sclerosis," and "clinical trials" was performed. An additional search on the clinicaltrials.gov website with the same key words was used to find registered clinical trials of MS therapies that included these visual outcome measures. RESULTS: As demonstrated by multiple clinical trials, LCLA and OCT measures are sensitive to treatment effects in MS. LCLA has been used in many clinical trials to date, and findings suggest that 7 letters of LCLA at the 2.5% contrast level are meaningful change. Few clinical trials using the benefits of OCT have been performed, although results of observational studies have solidified the ability of OCT to assess change in retinal structure. Continued accrual of clinical trial and observational data is needed to validate the use of OCT in clinical trials, but preliminary work suggests that an intereye difference in retinal nerve fiber layer thickness of 5-6 μm is a clinically meaningful threshold that identifies an optic nerve lesion in MS. CONCLUSIONS:Visual impairment represents a significant component of overall disability in MS. LCLA and OCT enhance the detection of visual pathway injury and can be used as measures of axonal and neuronal integrity. Continued investigation is ongoing to further incorporate these vision-based assessments into clinical trials of MS therapies.
Authors: Stephanie B Syc; Christina V Warner; Girish S Hiremath; Sheena K Farrell; John N Ratchford; Amy Conger; Teresa Frohman; Gary Cutter; Laura J Balcer; Elliot M Frohman; Peter A Calabresi Journal: Mult Scler Date: 2010-06-08 Impact factor: 6.312
Authors: Julia Button; Omar Al-Louzi; Andrew Lang; Pavan Bhargava; Scott D Newsome; Teresa Frohman; Laura J Balcer; Elliot M Frohman; Jerry Prince; Peter A Calabresi; Shiv Saidha Journal: Neurology Date: 2017-01-11 Impact factor: 9.910
Authors: Diego Cadavid; Laura Balcer; Steven Galetta; Orhan Aktas; Tjalf Ziemssen; Ludo Vanopdenbosch; Jette Frederiksen; Mark Skeen; Glenn J Jaffe; Helmut Butzkueven; Focke Ziemssen; Luca Massacesi; Yi Chai; Lei Xu; Stefanie Freeman Journal: Lancet Neurol Date: 2017-02-15 Impact factor: 44.182
Authors: Robert J Fox; Christopher S Coffey; Merit E Cudkowicz; Trevis Gleason; Andrew Goodman; Eric C Klawiter; Kazuko Matsuda; Michelle McGovern; Robin Conwit; Robert Naismith; Akshata Ashokkumar; Robert Bermel; Dixie Ecklund; Maxine Koepp; Jeffrey Long; Sneha Natarajan; Srividya Ramachandran; Thomai Skaramagas; Brenda Thornell; Jon Yankey; Mark Agius; Khurram Bashir; Bruce Cohen; Patricia Coyle; Silvia Delgado; Dana Dewitt; Angela Flores; Barbara Giesser; Myla Goldman; Burk Jubelt; Neil Lava; Sharon Lynch; Augusto Miravalle; Harold Moses; Daniel Ontaneda; Jai Perumal; Michael Racke; Pavle Repovic; Claire Riley; Christopher Severson; Shlomo Shinnar; Valerie Suski; Bianca Weinstock-Gutman; Vijayshree Yadav; Aram Zabeti Journal: Contemp Clin Trials Date: 2016-08-10 Impact factor: 2.226
Authors: Ari J Green; Jeffrey M Gelfand; Bruce A Cree; Carolyn Bevan; W John Boscardin; Feng Mei; Justin Inman; Sam Arnow; Michael Devereux; Aya Abounasr; Hiroko Nobuta; Alyssa Zhu; Matt Friessen; Roy Gerona; Hans Christian von Büdingen; Roland G Henry; Stephen L Hauser; Jonah R Chan Journal: Lancet Date: 2017-10-10 Impact factor: 79.321
Authors: Jeffrey M Gelfand; Douglas S Goodin; W John Boscardin; Rachel Nolan; Ami Cuneo; Ari J Green Journal: PLoS One Date: 2012-05-23 Impact factor: 3.240
Authors: Tobias Ruck; Ali Maisam Afzali; Karl-Friedrich Lukat; Maria Eveslage; Catharina C Gross; Steffen Pfeuffer; Stefan Bittner; Luisa Klotz; Nico Melzer; Heinz Wiendl; Sven G Meuth Journal: BMC Neurol Date: 2016-03-10 Impact factor: 2.474
Authors: Rhian Raftopoulos; Simon J Hickman; Ahmed Toosy; Basil Sharrack; Shahrukh Mallik; David Paling; Daniel R Altmann; Marios C Yiannakas; Prasad Malladi; Rose Sheridan; Ptolemaios G Sarrigiannis; Nigel Hoggard; Martin Koltzenburg; Claudia A M Gandini Wheeler-Kingshott; Klaus Schmierer; Gavin Giovannoni; David H Miller; Raju Kapoor Journal: Lancet Neurol Date: 2016-01-26 Impact factor: 44.182
Authors: Hong Jiang; Giovana Rosa Gameiro; Yi Liu; Ying Lin; Jeffrey Hernandez; Yuqing Deng; Giovanni Gregori; Silvia Delgado; Jianhua Wang Journal: Am J Ophthalmol Date: 2020-01-08 Impact factor: 5.258
Authors: Nic Skorupka; Andrei Miclea; Katarzyna Aleksandra Jalowiec; Christoph Bocksrucker; Nicole Kamber; Andrew Chan; Behrouz Mansouri Taleghani; Robert Hoepner; Anke Salmen Journal: Transfus Med Hemother Date: 2019-11-14 Impact factor: 3.747